Morgan Stanley’s Proshares UltraPro NASDAQ Biotechnology UBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-805
| Closed | -$26K | – | 6864 |
|
|
2019
Q4 | $26K | Hold |
805
| – | – | ﹤0.01% | 6047 |
|
|
2019
Q3 | $15K | Hold |
805
| – | – | ﹤0.01% | 6103 |
|
|
2019
Q2 | $21K | Hold |
805
| – | – | ﹤0.01% | 5929 |
|
|
2019
Q1 | $24K | Hold |
805
| – | – | ﹤0.01% | 5959 |
|
|
2018
Q4 | $16K | Hold |
805
| – | – | ﹤0.01% | 6069 |
|
|
2018
Q3 | $36K | Sell |
805
-100
| -11% | -$4.04K | ﹤0.01% | 5978 |
|
|
2018
Q2 | $30K | Sell |
905
-1
| -0.1% | -$31 | ﹤0.01% | 6047 |
|
|
2018
Q1 | $29K | Buy |
906
+606
| +202% | +$22.3K | ﹤0.01% | 6044 |
|
|
2017
Q4 | $10K | Sell |
300
-600
| -67% | -$20.5K | ﹤0.01% | 6224 |
|
|
2017
Q3 | $35K | Sell |
900
-2
| -0.2% | -$70 | ﹤0.01% | 5885 |
|
|
2017
Q2 | $29K | Sell |
902
-100
| -10% | -$2.81K | ﹤0.01% | 6008 |
|
|
2017
Q1 | $28K | Sell |
1,002
-400
| -29% | -$10.5K | ﹤0.01% | 5988 |
|
|
2016
Q4 | $30K | Buy |
1,402
+1,010
| +258% | +$23.9K | ﹤0.01% | 5893 |
|
|
2016
Q3 | $11K | Sell |
392
-200
| -34% | -$5.7K | ﹤0.01% | 6099 |
|
|
2016
Q2 | $13K | Buy |
+592
| New | +$15K | ﹤0.01% | 5996 |
|
|
2015
Q3 | – | Sell |
-17
| Closed | -$2K | – | 6803 |
|
|
2015
Q2 | $2K | Buy |
+17
| New | +$1.57K | ﹤0.01% | 6528 |
|
Other funds holding UBIO
Morgan Stanley's UBIO Position: Q1 2020 in Review
Morgan Stanley sold out of Proshares UltraPro NASDAQ Biotechnology (UBIO) in Q1 2020, closing a stake of 805 shares — an estimated $26K sold.
Morgan Stanley first reported a position in UBIO in Q2 2015 and held it in 16 quarters. The position peaked at $36K in Q3 2018. 1 fund tracked by Wall St. Rank holds UBIO as of Q1 2020.
- Morgan Stanley reported no remaining Proshares UltraPro NASDAQ Biotechnology position as of Q1 2020 after selling out during the quarter.
- Morgan Stanley sold 805 Proshares UltraPro NASDAQ Biotechnology shares in Q1 2020, an estimated $26K.
- Morgan Stanley first reported a position in Proshares UltraPro NASDAQ Biotechnology in Q2 2015 and held it in 16 quarters.
- Morgan Stanley's Proshares UltraPro NASDAQ Biotechnology position peaked at $36K in Q3 2018.
- 1 fund tracked by Wall St. Rank held Proshares UltraPro NASDAQ Biotechnology as of Q1 2020.
Based on Morgan Stanley's 13F filing for Q1 2020, filed 15 May 2020.